Cronos Group Inc.

TSX:CRON Rapport sur les actions

Capitalisation boursière : CA$1.4b

Cronos Group Croissance future

Future contrôle des critères 4/6

Cronos Group devrait augmenter ses bénéfices et ses revenus de 97.5% et de 17.7% par an respectivement, tandis que le BPA devrait croître de croître de 73.8% par an.

Informations clés

97.5%

Taux de croissance des bénéfices

73.80%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices39.5%
Taux de croissance des recettes17.7%
Rendement futur des capitaux propresn/a
Couverture par les analystes

Low

Dernière mise à jour04 May 2026

Mises à jour récentes de la croissance future

Recent updates

Mise à jour de l'analyse • Apr 25

CRON: Partial Rescheduling Hopes Will Test Lean Cost Base Execution

Analysts have raised their Cronos Group price target to CA$4.50, citing expectations for slightly stronger revenue growth, modestly better profit margins, and a lower assumed future P/E, following recent bullish coverage and a favorable view on partial cannabis rescheduling. Analyst Commentary Recent research coverage on Cronos Group has centered on how potential regulatory shifts and brand positioning could influence the company’s path to improved profitability and valuation.
Mise à jour de l'analyse • Apr 11

CRON: Canadian Brand Strength And Lean Cost Base Will Support Future Upside

Analysts have reset their price target for Cronos Group to CA$4.50, reflecting fresh coverage that highlights the company’s established Canadian brands, its focus on scaling revenue with a lean cost base, and cultivation practices that are expected to support profitability trends. Analyst Commentary Recent coverage frames Cronos Group as a company with established Canadian brands and a focus on keeping its cost base lean while scaling revenue.
Mise à jour de l'analyse • Mar 28

CRON: Lean Cost Base And Brand Execution Will Shape Future Earnings Potential

Analysts have lifted their average price target for Cronos Group to CA$4.50, citing expectations for faster top line expansion, a leaner cost base and stronger profitability potential supported by the company's established Canadian cannabis brands and cultivation practices. Analyst Commentary Recent Street research has framed Cronos Group as a branded cannabis operator with established products in Canada and an emphasis on scaling revenue while keeping operating costs in check.
Mise à jour de l'analyse • Mar 13

CRON: Canadian Brand Strength And Rescheduling Shift Will Support Future Upside

Analysts have lifted their CA$ price target on Cronos Group, citing the company's Canadian cannabis brands, expectations for better profitability as revenue grows against a lean cost base, and confidence in its cultivation practices as key supports for the higher valuation range. Analyst Commentary Bullish Takeaways Bullish analysts highlight Cronos Group's portfolio of Canadian cannabis brands as a key support for the higher CA$ valuation range, arguing that strong consumer recognition can help sustain revenue as the company scales.
Mise à jour de l'analyse • Feb 27

CRON: Canadian Brand Strength And Rescheduling Shift Will Reshape Risk Reward Profile

Analysts have lifted their fair value estimate for Cronos Group to CA$4.24 from CA$3.95, pointing to higher assumed revenue growth and a lower future P/E multiple. They are factoring in recent bullish coverage highlighting the company’s established Canadian cannabis brands, lean cost base, and cultivation practices.
Mise à jour de l'analyse • Feb 13

CRON: Rescheduling Shift Will Expose Execution Risks And Restrain Earnings Upside

Analysts have lifted their CA$ fair value estimate for Cronos Group to CA$3.19, citing Street research that points to slightly higher expected revenue growth, modestly stronger profit margins, and a marginally lower future P/E assumption that together support a more constructive long term outlook. Analyst Commentary While the higher CA$3.19 fair value estimate reflects a more constructive stance on Cronos Group, not all research is leaning in the same direction.
Mise à jour de l'analyse • Jan 30

CRON: Rescheduling Shift And Product Expansion Will Shape A Balanced Earnings Outlook

Analysts have raised their price target on Cronos Group by a small amount to reflect updated assumptions for slightly higher revenue growth, a modestly stronger profit margin, and a marginally higher future P/E multiple. Analyst Commentary While some research points to a constructive view on Cronos Group, bearish analysts highlight a set of risks that could limit upside and keep the stock more range bound.
Mise à jour de l'analyse • Jan 16

CRON: Rescheduling Policy Shift Will Temper Optimism On Future Earnings Profile

Analysts have raised their price target for Cronos Group to US$3.19 from US$2.90, pointing to updated assumptions around slightly higher discount rates, more conservative revenue growth and a modestly stronger profit margin profile, alongside a similar forward P/E outlook. What's in the News President Trump directed the Attorney General to complete the rulemaking process to reschedule marijuana to Schedule III of the Controlled Substances Act, which directly touches U.S. cannabis policy and mentions Cronos Group among other publicly traded peers in the sector (Marijuana Herald).
Article d'analyse • Dec 13

Cronos Group Inc. (TSE:CRON) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected

Cronos Group Inc. ( TSE:CRON ) shareholders have had their patience rewarded with a 29% share price jump in the last...
Mise à jour de l'analyse • Sep 04

GrowCo Capacity And Global Markets Will Unlock Potential

The Consensus Analyst Price Target for Cronos Group has increased to CA$3.95, primarily reflecting a notable rise in the company's Future P/E multiple despite stable revenue growth expectations. What's in the News President Trump is considering reclassifying marijuana as a less dangerous drug, which could ease restrictions and benefit cannabis companies such as Cronos Group (The Wall Street Journal).
Article d'analyse • Aug 15

Cronos Group Inc.'s (TSE:CRON) 26% Share Price Surge Not Quite Adding Up

Cronos Group Inc. ( TSE:CRON ) shareholders would be excited to see that the share price has had a great month, posting...
User avatar
Nouvelle analyse • Apr 30

GrowCo Expansion Will Boost Operations But Strain Cash Flow

Investment in GrowCo and advancements in cannabis genetics are set to improve efficiency, enhance profitability, and strengthen market penetration.
Article d'analyse • May 31

We're Interested To See How Cronos Group (TSE:CRON) Uses Its Cash Hoard To Grow

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Article d'analyse • Apr 01

Cronos Group Inc.'s (TSE:CRON) P/S Is Still On The Mark Following 29% Share Price Bounce

The Cronos Group Inc. ( TSE:CRON ) share price has done very well over the last month, posting an excellent gain of...
Article d'analyse • Mar 02

We Think Cronos Group (TSE:CRON) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Article d'analyse • Feb 02

Revenues Tell The Story For Cronos Group Inc. (TSE:CRON)

When you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...
Article d'analyse • Nov 09

Companies Like Cronos Group (TSE:CRON) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Article d'analyse • Jul 17

We're Hopeful That Cronos Group (TSE:CRON) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Article d'analyse • Jun 20

Cronos Group Inc.'s (TSE:CRON) Earnings Haven't Escaped The Attention Of Investors

When you see that almost half of the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or...
Article d'analyse • Feb 09

We Think Cronos Group (TSE:CRON) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Prévisions de croissance des bénéfices et des revenus

TSX:CRON - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/2028250N/A72741
12/31/20272392348662
12/31/20262041752422
12/31/2025147-9026N/A
9/30/202513236-622N/A
6/30/202513018-920N/A
3/31/202512549-819N/A
12/31/202411841619N/A
9/30/2024111-481728N/A
6/30/2024102-571116N/A
3/31/202493-54-23N/A
12/31/202387-70-46-43N/A
9/30/202385-101-86-84N/A
6/30/202381-133-101-97N/A
3/31/202384-145-108-103N/A
12/31/202287-155-94-89N/A
9/30/202291-213-105-101N/A
6/30/202291-102-124-119N/A
3/31/202285-263-147-141N/A
12/31/202165-127-166-154N/A
9/30/202166-373-179-156N/A
6/30/202157-381-181-153N/A
3/31/202151-310-188-153N/A
12/31/202047-72-180-145N/A
9/30/202037101-185-160N/A
6/30/202031636-186-152N/A
3/31/202029929-192-155N/A
12/31/2019241,167-170-131N/A
9/30/2019211,089N/A-59N/A
6/30/201918479N/A-49N/A
3/31/201913293N/A-11N/A
12/31/201812-21N/A-8N/A
9/30/20189-8N/A-28N/A
6/30/20187-1N/A-16N/A
3/31/20185-2N/A-13N/A
12/31/20173-1N/A-4N/A
9/30/201741N/A-4N/A
6/30/201720N/A-8N/A
3/31/20171-1N/A-6N/A
12/31/20160-1N/A-5N/A
9/30/201620N/A-3N/A
6/30/201620N/A-2N/A
3/31/201631N/A-1N/A
12/31/201520N/A-1N/A
9/30/20150-4N/A-2N/A
6/30/2015-1-4N/A-2N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: CRON devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 3% ).

Bénéfices vs marché: CRON devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.

Croissance élevée des bénéfices: CRON devrait devenir rentable dans les 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de CRON ( 17.7% par an) devrait croître plus rapidement que le marché Canadian ( 4.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de CRON ( 17.7% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de CRON devrait être élevé dans 3 ans

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/07 17:06
Cours de l'action en fin de journée2026/05/07 00:00
Les revenus2025/12/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Cronos Group Inc. est couverte par 16 analystes. 2 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Jesse PytlakATB Cormark Historical (Cormark Securities)
Vahan AjamianBeacon Securities Limited
Nadine SarwatBernstein